Massachusetts-based PerkinElmer Inc announced that Dr Michelle McMurry-Heath has been elected to its board of directors, effective July 22, 2022. “I am pleased to welcome Michelle to PerkinElmer’s board and excited to see the Company benefit from both her deep research and advocacy experience along with her recognized leadership in influencing science policy and equitable access to medical innovation,” they tweeted.
“I am pleased to welcome Michelle to PerkinElmer’s board and excited to see the Company benefit from both her deep research and advocacy experience along with her recognized leadership in influencing science policy and equitable access to medical innovation,” said Alexis Michas, non-executive chairman of the board of PerkinElmer. “As PerkinElmer enters its next chapter of growth following a year of significant portfolio transformation, I look forward to Michelle’s contributions to our overall vision and strategy moving ahead.”
Dr Michelle McMurry-Heath is a medical doctor and molecular immunologist, and she took on the leadership of the Biotechnology Innovation Organization (BIO) as President and CEO in 2020. She arrived at the Biotechnology Innovation Organization (BIO) from Johnson & Johnson where she functioned as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. Before her tenure at J&J, Dr McMurry-Heath was also a critical science policy leader in government, conducting a thorough analysis of the National Science Foundation’s policies, programs and personnel. President Barack Obama then anointed her associate science director of the FDA’s Center for Devices and Radiological Health.
Dr McMurry-Heath was the founding director of the Aspen Institute’s Health, Biomedical Science, and Society Policy Program and obtained her early training in science policy from the Robert Wood Johnson Foundation. Dr McMurry-Heath also functions on the Board of Directors at Bioventus. She received her MD and PhD from Duke’s Medical Scientist Training Program, thus becoming the first African American to graduate from the prestigious program. She spent 12 years working on the research bench before taking policy and leadership roles in government and industry.